Payer+Provider's Health System Review
January 26, 2022
I have been following the controversy surrounding the approval of the new Alzheimer’s drug aducanumab with great interest. Until a year and a half ago, I worked as a neurologist in an adult general neurology clinic. Many of my patients had dem…